Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,131.20
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,282.84
(
-0.75%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 91500

Friday, 03/05/2010 5:10:07 PM

Friday, March 05, 2010 5:10:07 PM

Post# of 257253
Addendum on BMY’s buyout vig: Although the CEO transition effectively rules out a near-term sale of the company, BMY retains a considerable amount of deferred buyout vig, IMO.

The new CEO, Lamberto Andreotti, is 59—only a few years younger than the outgoing CEO—and Andreotti is not exactly from central casting.

A buyout in a couple of years at $40/sh would not be at all surprising, IMO. BMY has an impressive portfolio and pipeline for a midsized firm, and the market cap is small enough to be digestible by one of the big Big Pharma.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now